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ABSTRACT
Background: Neuroendocrine tumors (NETs) have a low incidence but relatively 
high prevalence. Over the last three decades, the incidence of NETs has risen 6-fold 
in the United States. We conducted an observational study to compare the incidence 
of NETs reported to the Kentucky Cancer Registry (KCR) versus that reported to 
Surveillance, Epidemiology, and End Results Program (SEER). We also provide a 
systematic review of the state of neuroendocrine tumors worldwide, and compare 
the available global and local published data.
Methods: KCR and SEER databases were queried for NET cases between 1995 
and 2015. A detailed literature review of epidemiological data for various nations 
worldwide summarize epidemiological data from various countries.
Results: KCR recorded 6179 individuals with newly diagnosed NETs between 
1995 and 2015. Between 1995-2012, the incidence of NETs in KCR increased from 3.1 
to 7.1 per 100,000 cases, while it increased from 3.96 to 6.61 in the SEER database. 
The incidence rates in both KCR and SEER databases were linear. 90.57% were 
Caucasians with 54.74% females. 27.67% of the Kentucky population was from the 
Appalachian region. Patients aged 50-64 years had the highest prevalence (38%). 
Lung NET (30.60%) formed the bulk of cases, followed by small intestine (16.82%), 
rectum/anus (11.35%) and colon (9.71%).
Conclusions: NETs incidence between 1995 and 2015 show a linear increase in 
both KCR and SEER databases. Because of this increased incidence it is imperative for 
community oncologists to familiarize themselves with this entity, which until recently 
was under-studied and with few viable treatment options.
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INTRODUCTION
Neuroendocrine tumors are frequently grouped 
with other rare malignancies, which limits drug 
development and clinical trial expansion for this 
important oncologic entity. Fortunately, the last 15 years 
have seen rapid changes in awareness and perception of 
general oncologists toward neuroendocrine tumors. As a 
result, there is not only an expansion of evidence-based 
standard of care data for the treatment of these patients, 
but future therapeutic drug developmental avenues also 
look promising. Robust epidemiological surveillance of 
this population helps us recognize the quantum of disease 
burden and unique patterns of disease presentation, 
which are key in the use of effective screening, targeted 
diagnostics, and treatments.
We performed a retrospective analysis of the 
Kentucky Cancer registry (KCR) and the Surveillance, 
Epidemiology, and End Results Program (SEER) 
databases between 1995 and 2015. Studies outside of the 
U.S. were also analyzed in terms of incidence, anatomical 
sites, grade, and survival. The aim of the study is to 
analyze epidemiologic and demographic data of newly 
diagnosed neuroendocrine tumors in Kentucky and 
compare this information with currently available global 
data.
RESULTS
We identified 6179 individuals with newly 
diagnosed NET between 2005 and 2015. We observed a 
steady rise in annual incidence of NET from 119 new cases 
in 1995 to 528 cases in 2015 (Table 1). After accounting 
for Kentucky’s population increase (from 4.183 million to 
4.425 million during those years), we determined that the 
corresponding incidence rate increased from 3.1 to 10.3 
per 100,000 population (Table 1). Of our study patients, 
90.57% were Caucasian with 54.74% females. Patients 
aged 50-64 years had the highest prevalence (38%). 
Geographically, 27.67% of our Kentucky population was 
from the Appalachian region. Lung NET (30.60%) formed 
the bulk of cases, followed by small intestine (16.82%), 
rectum/anus (11.35%) and colon (9.71%) (Table 2A). 
46.92% of females presented with localized disease as 
compared to 36.07% males. 26.45 % of African Americans 
NET patients were aged between 20-49 years as compared 
to 18.22% of Caucasian patients. Lung NET was highest 
among smokers, whereas small bowel NET was highest 
among nonsmokers.
The majority of cases (52%) were low grade, with 
22% high grade, 3% intermediate grade, and the rest 
unknown (Table 2B). Grading of tumors is based on the 
globally-accepted WHO criteria, which considers Ki 67 
<2% low grade, 2-20% intermediate grade, >20% high 
grade [1]. This grading system might be modified in the 
future based on recent data from Tang et al. [2] It should be 
noted that roughly 25% of newly diagnosed NET patients 
are histologically placed at either G2 or G3. These patients 
have a distinct clinicopathological course as compared to 
low grade (G1) NETs.
Unlike most other malignancies, NETs are usually 
diagnosed at an early stage. In our study population, 42% 
had local disease at the time of diagnosis, 22% had loco-
regional disease, 22% presented with distant metastatic 
disease, and the other 14% had an unknown status. Except 
for those with local disease, where 25% were females as 
compared to 16% males, the loco-regional and metastatic 
subgroups did not show any gender discrepancy. Staging 
has a profound impact on the choice of treatment, with 
early stage being curative with surgical resection alone, 
especially for low grade histology. As expected, 52% 
of our study population underwent surgery alone as the 
treatment of choice.
As far as age stratification is concerned, peak 
incidence was found in 50-64 year age group (38%), 
followed by 65-74 (25%), 20-49 (19%) and 75+ (18%). 
These data are in agreement with most found in the 
published literature.
Lastly, 27% of our study population reside in 
the Appalachian region. Multivariate analysis of the 
Appalachian population did not show significant 
aberration in patterns compared with the non-Appalachian 
population with regard to any of the previously discussed 
study variables.
DISCUSSION
Derived from the neural crest cells during 
development, NETs can arise from various primary 
sites in the body. Neuroendocrine tumors are commonly 
found in the gastrointestinal tract but it is not unusual to 
find neuroendocrine tumors in lungs, pancreas, thyroid, 
gonads, and other locations [3–5]. Besides site of origin, 
NETs can also be subdivided between secretory or non-
secretory subgroups based on production of hormones or 
into high grade, intermediate grade or low-grade tumors 
based on the pathology. There is substantial heterogeneity 
among all these subgroups in terms of natural history of 
disease progression, response to therapeutic agents, and 
overall survival. Despite their low incidence rate, all 
NETs harbor the potential for malignancy, rendering the 
term “carcinoid tumor,” adopted by previous researchers, 
inaccurate. In addition to their misnomer, the diagnosis 
criteria and classifications of NETs have been under 
debate since their discovery at the beginning of the last 
century. JACC, WHO, and ENETS criteria standards differ 
among each other, and the criteria for NETs from various 
sites may also vary within the same guideline. Along with 
the lack of population-based NET registries across the 
world in general, these variances have prevented us from 
elucidating the worldwide epidemiology of NETs over 
time. Rather, a multitude of studies emerged to assess 
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Table 2A: Site-specific prevalence of neuroendocrine tumors in Kentucky
Site Prevalence (%)
Lung 30.6
Small Intestine 16.82
Rectum/Anus 11.35
Colon 9.71
Pancreas 5.5
Others 12.91
Unknown 7.61
Table 1: KCR and SEER NETs cases, 2005-2015
Year
KCR
(age adjusted 
incidence)
SEER
(age adjusted 
incidence)
KCR
(Cases)
SEER
(Cases)
1995 3.1 3.96 119 1299
1996 3.6 4.12 138 1372
1997 3.6 4.29 141 1456
1998 4.7 4.73 188 1631
1999 5 4.76 204 1671
2000 5.3 4.9 218 3613
2001 5.2 4.67 214 3510
2002 5.5 5.14 232 3947
2003 5.2 5.29 226 4123
2004 5.9 5.44 257 4335
2005 5.8 5.56 257 4378
2006 6.3 5.94 281 4880
2007 7.4 6.16 342 5196
2008 7.4 6.27 351 5401
2009 7.2 6.38 346 5628
2010 8.2 6.57 405 5913
2011 7.1 6.61 351 6042
2012 8.4 414
2013 8.6 447
2014 10.4 520
2015 10.3 528
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the prognostic value of each classification scheme. In 
this systematic review, we examined NET cohort studies 
by country, focusing on the profile of NET composition 
and incidences, to gain a worldwide perspective of NET 
epidemiology.
Primary sites
Consistent with the SEER database, the most 
common NET sites in KCR database were lung, small 
intestine, and rectum-anus (Table 2A) [6]. A nation-wide 
study from Netherland also reported pulmonary NET 
being the most prevalent. In contrast, two studies from 
Denmark and Sweden reported small intestine NETs to 
be most prevalent [7, 8]. If only gastroenteropancreatic 
neuroendocrine tumors (GEP-NETs) were considered, 
studies in Argentina, France, and Norway reported the 
small intestine as being the most common anatomical 
location [9–11]. Table 3 summaries the three most 
prevalent NET sites globally. Appendix NET was prevalent 
among Western countries in general, which could be 
explained by accidental findings during appendectomy. 
The survival rates of appendix NET were also the most 
optimal, which might also result from early detections 
(Table 4). In contrast, rectal NET was particularly common 
in Asian populations [12–15]. Whether these distinctions 
resulted from genetic variations needs further research.
Grading and survival
From a global perspective, few countries reported 
grading data according to Ki-67 and/or mitotic counts 
due to the continuously evolving grading systems. 
The percentages of each grade varied among studies. 
Although a nation-wide, multicenter study in Korea 
reported a high G1 percentage of 92.3%, a regional study 
in China indicated that 73.9% of all graded cases were G3. 
Nevertheless, a consistent impression among all studies 
was that lower grade NETs demonstrated a better outcome 
in terms of survival. Tables 4 and 5 summarize global 
NET 5-year overall survival by site and by grade. Grade 
1, Grade 2, and Grade 3 in our Kentucky population were 
67.5%, 28.6%, and 3.9%, respectively (Table 2B). Table 6 
summarizes global prevalence of NETs by grade. Our data 
underscores the fact that roughly 25% of newly diagnosed 
NET patients in Kentucky present with either G2 or 
G3 histology. This is a significant number considering 
these intermediate grade and high grade NETs are often 
aggressive and have very limited treatment options.
Incidence
Unlike most malignancies, NET incidence has 
shown a constant incline. The cause of this increase is not 
entirely clear but experts have attributed the pattern to an 
increased awareness and improved diagnostics. The hike 
in incidence of this otherwise rare tumor has alerted public 
health stakeholders, which has resulted in establishment of 
specialized NET registries worldwide [16, 17]. A seminal 
paper from Yao et al. showed a 5-fold increase in incidence 
of NET from 1973 to 2004 [3]. Incidence of NET per Yao’s 
report is estimated to be 5.25 cases per 100,000 population. 
Similar observations were made by Tsikitis et al. in the GI 
NET subgroup [18]. Per their report, overall incidence of 
GI NETs increased in all sites except for appendix tumors. 
In Germany, the age-standardized incidence increased 
from 2.7 to 3.4 fold from 1976 to 2006 [19]. In Italy, the 
incidence increased from 0.7 to 5.3 between 1976 and 
2010 [20]. Based on recently published papers, increasing 
trends were also observed in China Japan, Korea, Norway, 
Netherlands, and Taiwan [11-15, 21]. Outside of the United 
States, incidence rates ranged from 1.41 to 5.86 based 
on studies published after 2000 [13, 15, 19, 20, 22-25]. 
Based on our analysis, the incidence of NETs reported in 
Kentucky according to the KCR database increased from 
3.1 (1995) to 10.3 (2015) per 100,000 cases. In contrast, 
according to SEER data, the incidence increased from 3.9 
to 6.61 between 1995 and 2012 (Figure 1).
Limitations
Since the beginning of the last century, the 
nomenclature, diagnostic criteria and classification of 
NETs have been evolving. “Carcinoid tumor”, a previous 
term adopted by several early studies, was inaccurate 
because all NETs harbor the potential for malignancy [7, 
26–30]. Older versions of the International Classification 
of Disease for Oncology excluded benign NETs. The 
WHO has changed grading criteria over time. All of these 
inconsistencies prevent achieving a clear comparison of 
Table 2B: Grade specific distribution of NETs in Kentucky
WHO 2010 Grading %
G1 52
G2 3
G3 22
Unknown 23
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Table 3: Top 3 primary sites of NETs, reported by country
Country Authors Years Sample size 1
st Most Common 
Primary Site
2nd Most 
Common 
Primary Site
3rd Most Common 
Primary Site
Argentina [9] NA 532(GEP-NET only)
Small Intestine 
(26.9%)1 Pancreas (25.2%)
Colon-Rectum-Anus 
(12.4%)
Austria 
(prospective 
study)
[22] 2004-2005 265 Stomach (23%) Appendix (21%) Small Intestine (15%)
Brazil [31] 1997-2009 773(GEP-NET only) Stomach (24.5%)
Small Intestine 
(20.8%) Rectum (20.5%)
Canada [23] 1994-2009 5619 Pancreas (25%) Colon(22.8%)
Small Intestine 
(21.6%)
Canada [25] 1990-2005 530 Small Intestine (55.3%)
Colon
(18.3%) Appendix (17.9%)
China [13] 2009-2013 248(GEP-NET only) Rectum (30.6%) Pancreas (23.4%) Gastric (13.3%)
China [32] 1991-2013
130
(NET with liver 
metastasis only)
Pancreas (65.4%) Stomach (10.8%) Small Intestine (5.4%)
China [33] 2011-2016 440(GEP-NET only) Stomach (24.3%) Rectum (24.1%) Pancreas (20.5%)
China 
(Hongkong) [34] 1994-2013
126
(GEP-NET only) Pancreas (34.9%) Rectum (33.3%) Stomach (8.7%)
Denmark [7] 1978-1989 1029 Small Intestine (29.4%)
Appendix 
(17.9%) Pulmonary (16.8%)
France [10] 2001-2002 668(GEP-NET only)
Small Bowel and 
Colon (43%) Pancreas (32%) Gastric (5%)
Germany [35] 2004-2007 1263 Pancreas (31%) Small Intestines (22%)
Colon and Rectum 
(11.4%)
Italy [36] 2004-2007 1203 Pancreas (31%) Lung(29%)
Ileum, Cecum, Colon, 
Rectum (13%)
Korea [14] 2000-2009 4951 (GEP-NET only) Rectum (48%) Stomach (14.6%), Colon (7.9%)
Lebanon [37] 2001-2012 89(GEP-NET) Pancreas (24.7%) Stomach (20.8%) Duodenum (18.2%)
Mexico [38] NA 495 (GEP-NET only) Pancreas (33.27%)
Stomach 
(28.02%) NA
Norway [24] 1993-2004 2030 Small Intestine (25.5%)
Lung and 
Bronchus (21%) Colon (8%)
Norway [11] 2003-2013 204 (GEP-NET only)
Small Intestines 
(29.4%)
Appendix 
(23.5%) Pancreas (16.2%)
Netherlands [21] 2001-2010 24759 Pulmonary (72.7%) Appendix (3.9%) Small Intestine (3.7%)
Spain [39] 2001-2008 907 Pancreas (34%) Jejunum-Ileum (15.6%) Appendix (9.4%)
Sweden [8] 1987-2012 7334 Small Intestine (32%) Appendix (23%)
Lung
(15%)
Taiwan [15] 1996-2008 2187 Rectum (25.4%) Lung/Bronchus (20%) Stomach (7.4%)
United 
States (by 
incidence)
[6] 2000-2012 64971 Lung(1.49%)
Small Intestine 
(1.05%) Rectum (1.04%)
1Values in parentheses are % of study cohort.
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Table 4: Five-year overall survival (OS) rate of NET by primary site (%)
Country Authors Rectum Lung Stomach Pancreas Colon Small Intestine Appendix
Canada [25] 100 70 73 70 84
Germany [19] 50 53 52 48 68 86
Norway [24] 74 54 45 43 41 59 74
Spain [39] 64.1 61.4 78.1 65.1
Duodenum 
(89.3), 
Jejunum-
Ileum 
(83.0)
100
Taiwan [21] 80.9 33.9 46.4 30.2 48.1 47.9 75.7
U.S. 
(Distant 
stage G1/
G2 only; 
diagnosed 
from 2000-
2012)
[6] 28 32 32 50 29 69
U.S. 
(reported 
by median 
OS time in 
years)
[6] 24.6 5.5 3.6 >30
Table 5: Five-year OS rate of NET by grade (%)
Country Authors G1 G2 G3
Argentina
(GEP-NET only; 
values were estimated 
from graph)
[9] >75 50-75 <25
China
(NET with liver 
metastasis only)
[32]
55.6
(surgical resected 
patients);
14.3 (non-surgically 
resected patients)
35.3
(surgical resected 
patients);
0 (non-surgically 
resected patients)
28.6
(surgical resected 
patients);
0 (non-surgically 
resected patients)
Korea
(GEP-NET only) [14] 94.2 70.38 42.96
Netherlands (based on 
the data from 2001-
2010)
[21] 80 63 20 (G3-LCNEC),6 (G3-SCNEC)
Spain
(GEP-NET only) [39] 83.3 77.1 43.5
U.S.
(reported by median 
OS time)
[6] 16.2 years 8.3 years 10 months (including G4)
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Table 6: Percentages of NET subtypes categorized according to WHO2010 criteria, reported by country
Country Author G1 G2 G3 Others (if applicable)
Argentina (GEP-
NET only) [9] 29.5% 35.9% 9.0% No data (25.6%)
Brazil [31] 73.2% 10.5% 16.3%
China [13] 3.1% 18.0% 73.9% MANEC (9.1%)
China [32] 27.3% 51.5% 21.2%
China [33] 29.5% 27.3% 43.2%
China
(Hong Kong) [34] 87.3% NA NA
Germany [35] 40.4% 51.1% 18.4%
Korea [14] 92.31% 4.85% 2.84%
Lebanon [37] 56.2% 11.2%, 20.2%, MANEC (12.4%)
Mexico [38] 64% 13% 23%
Netherlands [21] 17% 1% G3-LCNEC (7%)G3-SCNEC (75%)
Norway [11] 53.4% 24.0% 19.6%
Spain [39] 44.4% 37.8% 17.8%
U.S. [6] 51.0% 16.4% 32.5% (including G4)
Figure 1: NET incidence according to KCK (blue/series 1) and SEER (red/series 2) [6].
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different epidemiology studies overtime. Most countries 
do not have a nation-wide, population based NET 
registries. Single-center or regional studies cannot assess 
national incidence and prevalence convincingly.
MATERIALS AND METHODS
KCR is a part of NCI’s SEER program and has 
been collecting population-based cancer data since 1986. 
We sought Institutional Review Board approval prior to 
commencement of our study, then proceeded to review 
the KCR and SEER databases for all newly diagnosed 
neuroendocrine tumors in Kentucky between 1995 and 
2015. Incidence data were adjusted for population. 
Multivariate analysis was performed using SPSS to 
analyze various demographic and disease-specific study 
variables. Tumors were characterized by primary sites. 
Grading was based on the globally-accepted WHO criteria, 
which considers Ki 67 <2% low grade (G1), 2-20% 
intermediate grade (G2), >20% high grade (G3) [1].
Studies outside of the United States (U.S.) 
were reviewed according to search results from 
PubMed and Google Scholar. Examples of 
key words included: “neuroendocrine+tumor”; 
“neuroendocrine+neoplasm”; “neuroendocrine+prevalence”; 
“neuroendocrine+incidence”;” neuroendocrine+burden”; 
“neuroendocrine+epidemiology”; “carcinoid+tumor”; 
“carcinoid+incidence. Studies were sorted into tables 
according to authors, date, sample size, primary sites of 
tumor, grading, survival. Re-calculations were performed 
in some cases based on data from original studies in order 
to exclude unknown type and to obtain percentages of each 
tumor type and grade.
CONCLUSIONS
NETs incidence between 1995 and 2015 showed a 
linear increase in both KCR and SEER databases. NET 
incidence has undoubtedly increased over the past two 
decades. It is imperative for community oncologists 
to familiarize themselves with this entity, which until 
recently was under-studied and without many viable 
treatment options.
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